Wednesday, 18 Sep 2019

You are here

Changing Patterns of Drug Use in Pregnant Rheumatic Patients: Steroids Down, Biologics Up

Desai and coworkers analyzed public and private insurance claims data (2001-2012) to assess patterns of drug use in pregnant woment with RA, SLE, PsA and AS. Specifically, they looked at immunosuppressive drug use in the 3 months preceding and during pregnancy.

A total of 2,645 women actively treated with immunomodulatory agents prior to pregnancy were included. More women with PsA or AS stopped these immunomodulatory prescriptions upon becoming pregnant (61%) compared with women diagnosed with SLE (26%) or RA (34.5%). From the first to the third trimester, the proportion of women filling prescriptions for immunomodulatory agents decreased across all indications.

Overall, steroids (48.4%) and hydroxychloroquine (27.1%) were the most frequently used agents in pregnancy. Steroid prescription refills during pregnancy fell significantly from 54.4 to 42.4; rates for biologics increased from 5.1 to 16.6 between 2001 and 2012 (p<0.001).

While steroids and hydroxychloroquine remain the most widely prescribed treatments during pregnancy, biologic use is increasing in recent years. Presumably this reflects the increasing reports of TNF inhibitor safety in pregnant women.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I'd like to keep reading, but the link on the continue reading button is incorrect. Please help!
Thank you for bringing this to our attention - it's been corrected, and you can now access the correct link. -- Tammy J. Tilley, editor

More Like This

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.

Steroid Sparing Effects of Methotrexate and Mycophenolate in Uveitis

Patients with noninfectious uveitis (intermediate, posterior uveitis, or panuveitis) often require high dose corticosteroids and therefore may need steroid-sparing DMARD therapy. The FAST study investigated the corticosteroid-sparing effect of methotrexate or mycophenolate mofetil in adults with noninfectious uveitis.

Vitamin D Supplements Fail to Prevent Type 2 Diabetes - DUH!

A NEJM report shows that the use of vitamin D3 supplementation (4000 IU per day) in those without diabetes or vitamin D deficiency failed to significantly lower risk of type 2 diabetes (compared to placebo).

The rational for this report included observational data showing an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes.

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants

The comparative risk for gastrointestinal bleeding (GIB) with non-vitamin K antagonist oral anticoagulants (NOACs) was compared to vitamin K antagonists or anti-platelet agents in a recent metanalysis, which showed no significant difference in major GIB events between these agents.